Recursion Pharmaceuticals (RXRX) just moved onto many investors’ radar after Sanofi optioned the first development candidate ...
Recursion Pharmaceuticals reported past pipeline and collaboration progress, including positive REC-4881 and REC-1245 trial ...
Cathie Wood’s Ark Invest increased its exposure to AI infrastructure, digital platforms, and biotechnology, led by purchases ...
Recursion (RXRX) stock dips after $200M equity offering despite Sanofi (SNY) choosing its first AI drug candidate under a ...
Recursion Pharmaceuticals Inc. stocks have been trading up by 3.85 percent after upbeat AI-driven drug discovery partnership ...
Leading Healthcare Investors, including Janus Henderson Investors, Invus, Longaeva Partners, ARK Invest, Driehaus Capital Management and other ...
Recursion Pharmaceuticals, Inc. (“ Recursion ”) (NASDAQ: RXRX), a leading clinical-stage company pioneering AI-enabled drug discovery and development decoding biology to radically improve lives, today ...
Recursion Pharma launches a $200M equity offering and reports a Sanofi milestone but is rated a Hold on limited near-term ...
Recursion Pharmaceuticals Inc. RXRX shares are trending on Friday. Shares of the Utah-based clinical-stage biotechnology ...
Recursion Pharmaceuticals stock gained nearly 15% on Thursday thanks to a drug candidate update and milestone payment.
Pharmaceutical & Biotech Stock Introductory Series, Part 2, Episode 10/12]IntroductionRecursion Pharmaceuticals (RXRX) is a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results